Meta-Analysis Summary of Broiler Chicken Trials with Dietary Actigen® (2009-2011)
Abstract
Statistical meta-analyses of results from broiler trials in 2009-2011 using dietary Actigen® were conducted. Actigen® (Alltech, Inc., Nicholasville, Kentucky, USA) is a second-generation, yeast cell wall product considered to be a "growth permitter" through its roles in immune modulation and improved intestinal health. Parameters evaluated were dietary inclusion rates for Actigen®, age of birds, Body Weight (BW), feed conversion ratio or feed/gain ratio and mortality %. Nine reports were collected allowing 15 comparisons of negative control (nCON) diets and Actigen® supplemented diets fed during the entire trials. Similarly, 9 reports were collected allowing 11 comparisons of positive control (antibiotic supplemented) diets and Actigen® supplemented diets. When added to basal diets, Actigen® at average inclusion rates by phases of 520/400/347 g/tonne (n = 15) and broiler age of 41.87 days (n = 15) significantly and beneficially changed body weight by +0.129 kg (+5.41%), feed conversion ratio or feed/gain ratio by -0.046 (-2.54%) and mortality % by -0.76 (-10.5% relative to nCON). Compared with positive control (antibiotic) results, dietary Actigen® at average inclusion rates by phases of 535/331/238 g/tonne (n = 11) and broiler age of 43.64 days (n = 11) non significantly changed body weight by +0.016 kg (+0.62%), feed conversion ratio or feed/gain ratio by -0.003 (-0.17%) and mortality % by +0.57 (+7.97% relative to positive control). Broiler results for antibiotic or Actigen® supplemented diets were statistically equivalent. Comparisons between this present meta-analysis and those done previously on another yeast cell wall compound (Bio-Mos®) suggest that the second generation product Actigen® may be more effective in terms of growth promotion.
Keywords:
Actigen, antibiotic, broiler chicken, mannan oligosaccharide, meta-analysisArticle Metrics
License
Copyright (c) 2011 Asian Network for Scientific Information

This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.